These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1613128)

  • 1. Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine.
    Hermann DJ; Krol TF; Dukes GE; Hussey EK; Danis M; Han YH; Powell JR; Hak LJ
    J Clin Pharmacol; 1992 Feb; 32(2):176-83. PubMed ID: 1613128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative evaluation of the effects of labetalol, verapamil and diltiazem on antipyrine and indocyanine green clearances.
    Rocci ML; Vlasses PH; Lener ME; Fruncillo RA; Sirgo MA
    J Clin Pharmacol; 1989 Oct; 29(10):891-5. PubMed ID: 2592580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of P-glycoprotein enhances transport of imipramine across the blood-brain barrier: microdialysis studies in conscious freely moving rats.
    O'Brien FE; Clarke G; Fitzgerald P; Dinan TG; Griffin BT; Cryan JF
    Br J Pharmacol; 2012 Jun; 166(4):1333-43. PubMed ID: 22250926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of ranitidine and cimetidine on imipramine disposition.
    Wells BG; Pieper JA; Self TH; Stewart CF; Waldon SL; Bobo L; Warner C
    Eur J Clin Pharmacol; 1986; 31(3):285-90. PubMed ID: 3792426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of imipramine and three metabolites produced by isozyme CYP2D6 expressed in a human cell line.
    Su P; Coutts RT; Baker GB; Daneshtalab M
    Xenobiotica; 1993 Nov; 23(11):1289-98. PubMed ID: 8310712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The analysis and disposition of imipramine and its active metabolites in man.
    Sutfin TA; DeVane CL; Jusko WJ
    Psychopharmacology (Berl); 1984; 82(4):310-7. PubMed ID: 6427820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative bioavailability of imipramine (Tofranil) coated tablets in healthy volunteers.
    Ullmann U; Lehnfeld R; Bliesath H; Birkel M; Gebbing H; Gräve M; Wolf H
    Int J Clin Pharmacol Ther; 2001 Jun; 39(6):271-6. PubMed ID: 11430636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone.
    Lamberg TS; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 1998 Jun; 63(6):640-5. PubMed ID: 9663178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose of midazolam should be reduced during diltiazem and verapamil treatments.
    Backman JT; Olkkola KT; Aranko K; Himberg JJ; Neuvonen PJ
    Br J Clin Pharmacol; 1994 Mar; 37(3):221-5. PubMed ID: 8198928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of imipramine and desipramine.
    Sallee FR; Pollock BG
    Clin Pharmacokinet; 1990 May; 18(5):346-64. PubMed ID: 2185906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcium antagonists. Pharmacokinetic properties.
    Kates RE
    Drugs; 1983 Feb; 25(2):113-24. PubMed ID: 6339196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction.
    Bergstrom RF; Peyton AL; Lemberger L
    Clin Pharmacol Ther; 1992 Mar; 51(3):239-48. PubMed ID: 1544284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma levels of imipramine and metabolites in 68 hospitalized children.
    Preskorn SH; Bupp SJ; Weller EB; Weller RA
    J Am Acad Child Adolesc Psychiatry; 1989 May; 28(3):373-5. PubMed ID: 2738003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous determination of imipramine, desipramine and their 2- and 10-hydroxylated metabolites in human plasma and urine by high-performance liquid chromatography.
    Chen AG; Wing YK; Chiu H; Lee S; Chen CN; Chan K
    J Chromatogr B Biomed Sci Appl; 1997 May; 693(1):153-8. PubMed ID: 9200529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects.
    Spina E; Avenoso A; Campo GM; Scordo MG; Caputi AP; Perucca E
    Br J Clin Pharmacol; 1997 Mar; 43(3):315-8. PubMed ID: 9088587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of imipramine, desipramine and their hydroxy metabolites by reversed-phase chromatography with ultraviolet and coulometric detection.
    Foglia JP; Sorisio D; Perel JM
    J Chromatogr; 1991 Dec; 572(1-2):247-58. PubMed ID: 1818058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine.
    Brøsen K; Gram LF
    Eur J Clin Pharmacol; 1989; 37(2):155-60. PubMed ID: 2792169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy.
    Bauer LA; Stenwall M; Horn JR; Davis R; Opheim K; Greene L
    Clin Pharmacol Ther; 1986 Aug; 40(2):239-42. PubMed ID: 3731687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active metabolites of imipramine and desipramine in man.
    Potter WZ; Calil HM; Sutfin TA; Zavadil AP; Jusko WJ; Rapoport J; Goodwin FK
    Clin Pharmacol Ther; 1982 Mar; 31(3):393-401. PubMed ID: 7060321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of the route of administration of imipramine on imipramine and desipramine blood levels.
    Rigal J; Albin H; Fança X; Demotes-Mainard F; Vinçon G
    J Clin Psychopharmacol; 1989 Oct; 9(5):364-7. PubMed ID: 2677063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.